Literature DB >> 22907436

Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.

M Calao1, E O Sekyere, H J Cui, B B Cheung, W D Thomas, J Keating, J B Chen, A Raif, K Jankowski, N P Davies, M V Bekkum, B Chen, O Tan, T Ellis, M D Norris, M Haber, E S Kim, J M Shohet, T N Trahair, T Liu, B J Wainwright, H F Ding, G M Marshall.   

Abstract

Embryonal cancer can arise from postnatally persistent embryonal remnant or rest cells, which are uniquely characterized by the absence of p53 mutations. Perinatal overexpression of the MycN oncoprotein in embryonal cancer precursor cells causes postnatal rests, and later tumor formation through unknown mechanisms. However, overexpression of Myc in adult tissues normally activates apoptosis and/or senescence signals as an organismal defense mechanism against cancer. Here, we show that perinatal neuroblastoma precursor cells exhibited a transiently diminished p53 response to MycN oncoprotein stress and resistance to trophic factor withdrawal, compared with their adult counterpart cells from the TH-MYCN(+/+) transgenic mouse model of neuroblastoma. The adult stem cell maintenance factor and Polycomb group protein, Bmi1 (B-cell-specific Moloney murine leukemia virus integration site), had a critical role at neuroblastoma initiation in the model, by repressing p53 responses in precursor cells. We further show in neuroblastoma tumor cells that Bmi1 could directly bind p53 in a complex with other Polycomb complex proteins, Ring1A or Ring1B, leading to increased p53 ubiquitination and degradation. Repressed p53 signal responses were also seen in precursor cells for other embryonal cancer types, medulloblastoma and acute lymphoblastic leukemia. Collectively, these date indicate a general mechanism for p53 inactivation in some embryonal cell types and consequent susceptibility to MycN oncogenesis at the point of embryonal tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907436     DOI: 10.1038/onc.2012.368

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.

Authors:  Yaqiong Jin; Huanmin Wang; Wei Han; Jie Lu; Ping Chu; Shujing Han; Xin Ni; Baitang Ning; Dianke Yu; Yongli Guo
Journal:  Tumour Biol       Date:  2015-10-14

2.  Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Authors:  Belamy B Cheung; Owen Tan; Jessica Koach; Bing Liu; Michael S Y Shum; Daniel R Carter; Selina Sutton; Sela T Po'uha; Louis Chesler; Michelle Haber; Murray D Norris; Maria Kavallaris; Tao Liu; Geraldine M O'Neill; Glenn M Marshall
Journal:  Mol Oncol       Date:  2015-04-29       Impact factor: 6.603

3.  Long Noncoding RNA-Directed Epigenetic Regulation of Gene Expression Is Associated With Anxiety-like Behavior in Mice.

Authors:  Paola A Spadaro; Charlotte R Flavell; Jocelyn Widagdo; Vikram S Ratnu; Michael Troup; Chikako Ragan; John S Mattick; Timothy W Bredy
Journal:  Biol Psychiatry       Date:  2015-02-11       Impact factor: 13.382

Review 4.  Epigenetic regulation in medulloblastoma.

Authors:  Jiaqing Yi; Jiang Wu
Journal:  Mol Cell Neurosci       Date:  2017-12-18       Impact factor: 4.314

5.  G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Authors:  Danielle M Hsu; Saurabh Agarwal; Ashley Benham; Cristian Coarfa; Denae N Trahan; Zaowen Chen; Paris N Stowers; Amy N Courtney; Anna Lakoma; Eveline Barbieri; Leonid S Metelitsa; Preethi Gunaratne; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

6.  Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Authors:  Daniel R Carter; Selina K Sutton; Marina Pajic; Jayne Murray; Eric O Sekyere; Jamie Fletcher; Anneleen Beckers; Katleen De Preter; Frank Speleman; Rani E George; Michelle Haber; Murray D Norris; Belamy B Cheung; Glenn M Marshall
Journal:  Mol Oncol       Date:  2016-03-02       Impact factor: 6.603

Review 7.  Polycomb group proteins and MYC: the cancer connection.

Authors:  Leonidas Benetatos; George Vartholomatos; Eleftheria Hatzimichael
Journal:  Cell Mol Life Sci       Date:  2013-07-30       Impact factor: 9.261

Review 8.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

9.  Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Authors:  Daniel R Carter; Jayne Murray; Belamy B Cheung; Laura Gamble; Jessica Koach; Joanna Tsang; Selina Sutton; Heyam Kalla; Sarah Syed; Andrew J Gifford; Natalia Issaeva; Asel Biktasova; Bernard Atmadibrata; Yuting Sun; Nicolas Sokolowski; Dora Ling; Patrick Y Kim; Hannah Webber; Ashleigh Clark; Michelle Ruhle; Bing Liu; André Oberthuer; Matthias Fischer; Jennifer Byrne; Federica Saletta; Le Myo Thwe; Andrei Purmal; Gary Haderski; Catherine Burkhart; Frank Speleman; Katleen De Preter; Anneleen Beckers; David S Ziegler; Tao Liu; Katerina V Gurova; Andrei V Gudkov; Murray D Norris; Michelle Haber; Glenn M Marshall
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

10.  Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma.

Authors:  Verónica Freire-Benéitez; Nicola Pomella; Thomas O Millner; Anaëlle A Dumas; Maria Victoria Niklison-Chirou; Eleni Maniati; Jun Wang; Vinothini Rajeeve; Pedro Cutillas; Silvia Marino
Journal:  NAR Cancer       Date:  2021-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.